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Objectives This study sought to determine the risk of ischemic stroke (IS)/thromboembolism (TE) associated with renal im-
pairment and its incremental predictive value over established risk stratification scores (congestive heart failure,
hypertension, age 75 years, diabetes, previous stroke [CHADS2] and congestive heart failure, hypertension,
age 75 years, diabetes, previous stroke, vascular disease, age 65 to 74 years, sex category (female)
[CHA2DS2-VASc]) in patients with atrial fibrillation (AF).
Background Risk stratification schemes for prediction of IS/TE in patients with AF are validated but do not include renal im-
pairment.
Methods Patients diagnosed with nonvalvular AF and available estimated glomerular filtration rate (eGFR) data in a 4-hospital
institution between 2000 and 2010 were identified. The study population was stratified by renal impairment defined
by serum creatinine level and by eGFR measured at time of diagnosis of AF. Independent risk factors of IS/TE (includ-
ing renal impairment) were investigated in Cox regression models. The incremental predictive value of renal impair-
ment over CHADS2 and CHA2DS2-VASc were assessed with the c-statistic, net reclassification improvement, and inte-
grated discrimination improvement. We focused on the 1-year outcomes in our analyses.
Results Of 8,962 eligible individuals, 5,912 (66%) had nonvalvular AF and available eGFR data. Renal impairment by
both creatinine and eGFR definitions was associated with higher rates of IS/TE at 1 year, compared with normal
renal function. After adjustment for CHADS2 risk factors, renal impairment did not significantly increase the risk
of IS/TE at 1 year (hazard ratio: 1.06; 95% confidence interval [CI]: 0.75 to 1.49 for renal impairment; and haz-
ard ratio: 1.09; 95% CI: 0.84 to 1.41 for eGFR). When renal impairment was added to existing risk scoring sys-
tems for stroke/TE (CHADS2 and CHA2DS2-VASc), it did not independently add to the predictive value of the
scores, whether defined by serum creatinine level or eGFR. This was evident even when the analysis was con-
fined to only those patients with at least 1 year of follow-up.
Conclusions Renal impairment was not an independent predictor of IS/TE in patients with AF and did not significantly im-
prove the predictive ability of the CHADS2 or CHA2DS2-VASc scores. (J Am Coll Cardiol 2013;61:2079–87)
© 2013 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2013.02.035Both atrial fibrillation (AF) and chronic kidney disease
(CKD) are increasingly recognized as significant burdens of
morbidity and mortality of global proportions (1–11). Even
mild renal impairment has long-term consequences for
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3,587 individuals had CKD, which
was associated with increased risk of
IS/TE and bleeding (15), confirm-
ing observations of previous smaller
studies (14,16,17). This study also
showed the benefit of vitamin K
antagonist (VKA) therapy on
IS/TE outcomes in the setting of
CKD, although both VKA and
aspirin were associated with an
increased risk of bleeding (15).
Renal function is quantified by
urinary creatinine clearance or by
the estimated glomerular filtra-
tion rate (eGFR) (18–20), but
few studies have considered the
association between eGFR and
long-term outcomes in individu-
als with AF, and existing studies
have tended to consider renal
function as a dichotomous vari-
able (2– 4,14). Also, patients
with renal failure have been ex-
cluded from randomized trials of
IS prevention in AF.
The importance of risk predic-
tion tools for IS/TE (congestive
heart failure, hypertension, age
75 years, diabetes, previous
stroke [CHADS2] [21]; and
congestive heart failure, hyper-
tension, age 75 years, diabetes,
previous stroke, vascular disease,
age 65 to 74 years, sex category
(females) [CHA2DS2-VASc]
22]) in prognosis and treatment planning in AF patients is
ecognized by their inclusion in major international guide-
ines (23,24). Renal failure is included as a dichotomous
ariable in risk prediction tools for bleeding but not included in
isk prediction tools for IS/TE (25–27), although the possibil-
ty of adding renal impairment (as the little “c”) to the
HA2DS2-VASc score has been previously proposed (28,29).
In a small study of selected AF patients post-catheter ablation,
renal dysfunction—defined by eGFR60 ml/min/1.73 m2—
independently increased the risk of TE (hazard ratio [HR]:
6.8; 95% confidence interval [CI]: 4.2 to 12.1) (30). There-
fore, better understanding of the impact of renal function
on IS/TE outcomes in a more representative “real-world”
population of AF patients is required.
The present study represents the first analysis to consider
the association between renal function, as measured by
serum creatinine level or eGFR, and the risk of IS/TE
events in a “real-world” population of individuals with
AF, unrestricted by age or comorbidity. We also inves-
Abbreviations
and Acronyms
AF  atrial fibrillation
CHADS2  congestive
heart failure, hypertension,
age >75 years, diabetes,
previous stroke
CHA2DS2-VASc 
congestive heart failure,
hypertension, age >75
years, diabetes, previous
stroke, vascular disease,
age 65 to 74 years, sex
category (female)
CI  confidence interval
CKD  chronic kidney
disease
eGFR  estimated
glomerular filtration rate
HAS-BLED  hypertension,
abnormal renal/liver
function, stroke, bleeding
history or predisposition,
labile international
normalized ratio, elderly
(>65 years), drugs/alcohol
concomitantly
HR  hazard ratio
IDI  integrated
discrimination improvement
IS  ischemic stroke
NRI  net reclassification
improvement
OAC  oral anticoagulation
TE  thromboembolism
VKA  vitamin K
antagonisttigated the incremental predictive value of adding renal ifunction to established IS risk scores in AF (CHADS2
and CHA2DS2-VASc).
Methods
Study population. The methods of the Loire Valley Atrial
Fibrillation Project have been previously reported (31).
Patients were followed from the first record of AF after
January 1, 2000 (i.e., index date) up to the latest data
collection at the time of study (December 2010) (see the
Methods section in the Online Appendix). Treatment at
discharge was obtained by screening hospital stay reports,
and information on comorbidities was obtained from the
computerized coding system. Patients were excluded from
the study if there were no available data with regard to the
baseline serum creatinine level at the time of first diagnosis
of AF (Fig. 1). For each patient, the CHADS2 (21);
CHA2DS2-VASc (22); and hypertension, abnormal renal/
liver function, stroke, bleeding history or predisposition,
labile international normalized ratio, elderly (65 years),
drugs/alcohol concomitantly (HAS-BLED) (25) scores
were calculated (Table 1).
Assessment of renal function. Serum creatinine levels
were taken at baseline, which was at first diagnosis of AF.
Index date was the time of the first record of AF and thus
the serum creatinine (and hence eGFR) measurement was
from that index date.
Renal impairment was defined as reported history of renal
failure or baseline serum creatinine level of 133 mol/l in
en and 115 mol/l in women (32). To convert serum
creatinine from mol/l to mg/dl, the former was multiplied
y a conversion factor of 88.4. Current consensus guidelines
tate that prediction equations have greater consistency and
ccuracy than serum creatinine in the assessment of GFR
18–20,33–35). In addition, prediction equations are equiva-
ent or better than 24-h urine creatinine clearance in all
ut 1 study (19,20,36). The eGFR (ml/min/1.73 m2) was
calculated (see the Methods section in the Online Appendix).
Outcomes. During follow-up, information on outcomes of
TE (including peripheral artery embolism and transient
ischemic attack), stroke (ischemic or hemorrhagic), bleed-
ing, and all-cause mortality were recorded. In this study, the
outcome of interest was IS/TE. Hemorrhagic strokes were
excluded in our analyses.
Statistical analysis. The study population was stratified
into 3 categories according to eGFR (in ml/min/1.73 m2),
orresponding to the stages of CKD: 60, 30 to 59, and
30 (Fig. 1) (18–20). Because data with regard to proteinuria
ere not available, stage of renal impairment could not be
efined. Baseline characteristics were determined separately for
he 3 eGFR strata, and differences were investigated with the
hi-square test for categorical covariates and the Kruskal-
allis test for continuous covariates. Baseline characteristics
ere also determined by the presence or absence of renalmpairment and then further stratification by eGFR.
r
w
b
S
c
e
a
i
a
C
p
m
a
c
m
c
r
i
i
(
m
p
1
m
d
f
t
u
m
r
t
d
c
t
u
p
s
t
N
s
N
R
O
2081JACC Vol. 61, No. 20, 2013 Banerjee et al.
May 21, 2013:2079–87 Renal Impairment and Stroke Risk in AFFirst, overall rates of IS/TE were calculated for patients
with CHADS2 and CHA2DS2-VASc scores. Thereafter,
ates were determined separately for patients with and
ithout renal impairment and by eGFR separately and then
y renal impairment with further stratification by eGFR.
econd, Cox proportional-hazard regression models were
onstructed to investigate whether renal impairment and
GFR were independent predictors of IS/TE. The risks
ssociated with renal impairment and eGFR were estimated
n a univariate analysis, a sex- and age-adjusted analysis, an
nalysis adjusted for the risk factors included in the
HADS2 score, and a multivariate analysis adjusted for all
baseline characteristics in Table 1, which were statistically
significant (p  0.05). All analyses were repeated by eGFR
category and by combined stratification by renal impairment
and eGFR. Furthermore, to test whether the results were
influenced by patients initiating treatment with VKA, we
performed additional analyses excluding patients at the
initiation of such treatment.
The value of adding renal impairment and eGFR to the
CHADS2 score was evaluated by Net Reclassification Im-
rovement (NRI) and Integrated Discrimination Improve-
ent (IDI), as previously described (37). Finally, we also
ssessed the predictive capability of CHADS2 with
-statistics estimated from Cox regression models with the
ethod described by Liu et al. (38). In estimating the
-statistics, the CHADS2 score was analyzed as categoric
isk groups (low/intermediate/high), and the effect of add-
Figure 1 Study Population
Patient characteristics shown, by renal impairment and by estimated glomerular fing renal impairment to the score was determined. AThe NRI, IDI, and the c-statistic were used to test the
mpact of adding renal impairment to the 2 scoring systems
CHADS2 and CHA2DS2-VASc) in 4 different statistical
odels by adding: 1) 1 point for renal impairment; 2) 1
oint for eGFR  30 to 59 and 2 points for eGFR 30; 3)
point for renal impairment and 2 points for renal impair-
ent and eGFR30; and 4) 1 point for eGFR30. These
ifferent models use the most common definitions of renal
unction (by eGFR and serum creatinine) in different ways
o add to CHADS2 and CHA2DS2-VASc in the most
ser-friendly way. This approach assesses which (if any)
ethod of adding renal impairment to either of the stroke
isk scores added predictive value. We felt it was impor-
ant to explore the impact of renal (dys)function in
ifferent statistical models, because renal impairment is a
ontinuum and not just a “yes/no” phenomenon. In short,
he different tested models aimed to find the most
ser-friendly and useful stroke risk prediction tool incor-
orating renal function.
A 2-sided p value 0.05 was considered statistically
ignificant. All analyses were performed with SPSS statis-
ical software (version 18.0, IBM, Chicago, Illinois), and
RI and IDI calculations were performed with R statistical
oftware (version 2.12.2, University of Auckland, Auckland,
ew Zealand).
esults
f 8,962 eligible individuals, 5,912 (66%) had nonvalvular
rate (eGFR). VKA  vitamin K antagonist.ltrationF and available serum creatinine data, allowing the eGFR
d
r
y
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Renal Impairment and Stroke Risk in AF May 21, 2013:2079–87Characteristics of Patients With AF by Renal Impairment and eGFRTable 1 Characteristics of Patients With AF by Renal Impairment and eGFR
Overall Study Population
Patients With Renal Impairment
eGFR (ml/min/1.73 m2)
p Value
Normal Renal Function
(n  4,375)
Renal Impairment
(n  1,537) p Value
30–59
(n  1,196)
<30
(n  341)
Age, yrs 68.2 15.7 75.8 10.9 0.001 74.9 10.8 79.3 9.5
Female 1,777 (40.6) 419 (27.3) 0.001 234 (19.6) 185 (54.3) 0.001
Type of AF
Paroxysmal 2,635 (60.2) 760 (49.4) 0.001 583 (48.7) 177 (51.9) 0.49
Permanent 1501 (34.3) 688 (44.8) 541 (45.2) 147 (43.1)
Persistent 239 (5.5) 89 (5.8) 72 (6.0) 17 (5.0)
Comorbidities
Hypertension 1,780 (40.7) 757 (49.3) 0.001 548 (45.8) 209 (61.3) 0.001
Diabetes 653 (14.9) 315 (20.5) 0.001 220 (18.4) 95 (27.9) 0.001
Previous stroke 315 (7.2) 133 (8.7) 0.06 94 (7.9) 39 (11.4) 0.11
Coronary artery disease 1,215 (27.8) 631 (41.1) 0.001 503 (42.1) 128 (37.5) 0.16
Any vascular disease 1,336 (30.5) 698 (45.4) 0.001 549 (45.9) 149 (43.7) 0.33
Heart failure 2,083 (47.6) 1,015 (66.0) 0.001 760 (63.5) 255 (74.8) 0.001
Liver impairment 14 (0.3) 4 (0.3) 0.72 3 (0.3) 1 (0.3) 0.99
Dyslipidemia 821 (18.8) 327 (21.3) 0.03 254 (21.2) 73 (21.4) 0.76
Smoking 531 (12.1) 213 (13.9) 0.08 165 (13.8) 48 (14.1) 0.85
Pacemaker/ICD 689 (15.7) 349 (22.7) 0.001 277 (23.2) 72 (21.1) 0.54
Bleeding risk factors
Previous bleeding 192 (4.4) 91 (5.9) 0.02 64 (5.4) 27 (7.9) 0.20
Labile INR 80 (1.8) 24 (1.6) 0.49 15 (1.3) 9 (2.6) 0.19
Anemia 21 (0.5) 16 (1.0) 0.02 11 (0.9) 5 (1.5) 0.68
NSAIDs 6 (0.1) 2 (0.1) 0.95 2 (0.2) 0 (0.0) 0.75
Drugs 717 (16.4) 365 (23.7) 0.001 290 (24.2) 75 (22.0) 0.50
Cancer 72 (1.6) 32 (2.1) 0.26 22 (1.8) 10 (2.9) 0.45
Excessive risk of falls 40 (0.9) 23 (1.5) 0.06 15 (1.3) 8 (2.3) 0.34
Thrombocytopenia 4 (0.1) 1 (0.1) 0.76 1 (0.1) 0 (0.0) 0.87
Antithrombotic agents
Vitamin K antagonist 2,295 (52.5) 796 (51.8) 0.58 654 (54.7) 142 (46.9) 0.001
Antiplatelet 1,349 (30.8) 525 (34.2) 0.002 408 (34.1) 117 (39.4) 0.52
Any antithrombotic 3,238 (74.0) 1127 (73.3) 0.21 892 (74.6) 235 (78.1) 0.001
Heart failure therapy
ACEI 779 (17.8) 350 (22.8) 0.06 283 (23.7) 67 (19.6) 0.02
Beta-blocker 981 (22.4) 425 (27.7) 0.16 344 (28.8) 81 (23.8) 0.004
Digoxin 563 (12.9) 206 (13.4) 0.11 166 (13.9) 40 (11.7) 0.14
Diuretic 807 (18.4) 467 (30.4) 0.001 348 (29.1) 119 (34.9) 0.07
Antiarrhythmic agent 1,222 (27.9) 443 (28.8) 0.52 347 (29.0) 96 (28.2) 0.49
Calcium channel blocker 157 (3.6) 70 (4.6) 0.01 52 (4.3) 18 (5.3) 0.12
CHADS2
Low (score  0) 1,084 (24.8) 127 (8.3) 0.001 122 (10.2) 5 (1.5) 0.001
Intermediate (score  1) 1,119 (25.6) 373 (24.3) 318 (26.6) 55 (16.1)
High (score 2) 2,172 (49.6) 1037 (67.5) 756 (63.2) 281 (82.4)
CHA2DS2-VASc
Low (score  0) 475 (10.9) 38 (2.5) 0.001 37 (3.1) 1 (0.3) 0.001
Intermediate (score  1) 682 (15.6) 91 (5.9) 86 (7.2) 5 (1.5)
High (score 2) 3,218 (73.6) 1408 (91.6) 1073 (89.7) 335 (98.2)
HAS-BLED
Low (score  0) 1,030 (23.5) 101 (6.6) 0.001 95 (7.9) 6 (1.8) 0.001
Moderate (score  1–2) 1,628 (37.2) 544 (35.4) 480 (40.1) 64 (18.8)
High (score 3) 1,717 (39.2) 892 (58.0) 621 (51.9) 136 (39.9)
Values are mean  SD or n (%). According to the congestive heart failure, hypertension, age 75 years, diabetes, previous stroke (CHADS2) and congestive heart failure, hypertension, age 75 years,
iabetes, previous stroke, vascular disease, age 65 to 74 years, sex category (female) (CHA2DS2-VASc) scores, patients with a score of 0 on either schema were considered as “low risk,” 1 as “intermediate
isk,” and2 as “high risk” of stroke and thromboembolism. The Hypertension, Abnormal renal/liver function, Stroke, Bleeding history or predisposition, Labile International Normalized Ratio, Elderly (65
ears), Drugs/alcohol concomitantly (HAS-BLED) score is a validated scoring system for bleeding risk stratification in atrial fibrillation (AF) patients (25). Patients with HAS-BLED score of 0 to 2 were deemed
o have “low-moderate” bleeding risk, and those with HAS-BLED score of 3 were classified as “high” bleeding risk. CHADS2 (1 point each for heart failure, hypertension, age75 and diabetes, and 2 points
for prior stroke or thromboembolism); CHA2DS2-VASc (1 point for heart failure, hypertension, diabetes, vascular disease, age 65 to 74, and female sex; 2 points for prior stroke or thromboembolism and age75).
ACEI  angiotensin-converting enzyme inhibitor; eGFR  estimated glomerular filtration rate; ICD  implantable cardiac defibrillator; INR  international normalized ratio.
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May 21, 2013:2079–87 Renal Impairment and Stroke Risk in AFto be calculated (Fig. 1). Of the cohort, 3,944 individuals
had 1 year of follow-up, whereas 1,444 individuals had 2
to 5 years of follow-up, and 524 had 6 to 10 years of
follow-up. Thus, 14,499 patient-years of follow-up were
included in the analysis, with mean follow-up of 2.45 
3.56 years. We focused on the 1-year outcomes in our
analyses.
Of the cohort, 1,537 (26%) individuals had renal impair-
ment, and of these, 341 (5.8%) had eGFR 30 ml/min/
1.73 m2 (Fig. 1). Online Figure 1 illustrates the study
opulation by eGFR alone. Baseline characteristics are
hown in Table 1 by renal impairment and eGFR category
nd in Online Table 1 by eGFR category. Individuals with
enal impairment were older, more likely to be male, less
ikely to have paroxysmal AF, more likely to have comor-
idities, and at higher risk of stroke/TE (assessed by
HADS2 and CHA2DS2-VASc scores) and bleeding (as-
sessed by HAS-BLED score) (Table 1). Similar trends were
present when those with renal impairment were further
stratified by eGFR (Table 1) and when the overall popula-
tion was stratified by eGFR (Online Table 1).
Of 434 IS/TE events, 171 (39.4%) occurred within the
first year. Table 2 shows the rates of stroke/TE per 100
erson-years according to the presence or absence of renal
mpairment in patients with CHADS2 score  0 and in the
verall population. Subjects with normal renal function had
ower event rates for IS/TE at 1 year. Patients with renal
mpairment had a higher rate of stroke/TE, and patients
ith eGFR 30 ml/min/1.73 m2 had a higher rate than
hose patients with eGFR 30 to 59 ml/min/1.73 m2 in the
Rate of Stroke/TE per 100 Person-Years in AllP ients and in Patients With CHADS2 Score  0Wi h and Without R al Impai ment
Table 2
Rate of Stroke/TE p r 100 Person-Years in All
Patients and in Patients With CHADS2 Score  0
With and Without Renal Impairment
1-Yr Follow-Up
Person-Yrs
Stroke/TE
Events
Stroke/TE
Rate (CI)
Overall (whole cohort)
Total 3,669 171 4.7 (3.5–6.2)
eGFR 60 1,863 64 3.4 (2.4–4.8)
eGFR  30–59 1,610 92 5.7 (4.2–7.8)
eGFR 30 196 15 7.7 (4.3–13.6)
Normal renal function 2,738 119 4.4 (3.2–5.9)
Renal impairment 931 52 5.6 (3.9–8.1)
eGFR  30–59 735 37 5.0 (3.3–7.6)
eGFR 30 196 15 7.7 (4.3–13.6)
CHADS2  0
Total 688 11 1.6 (0.8–3.0)
eGFR 60 521 9 1.7 (0.9–3.4)
eGFR  30–59 163 2 1.2 (0.3–5.0)
eGFR 30 4 0 —
Normal renal function 614 10 1.6 (0.8–3.2)
Renal impairment 74 1 1.4 (0.2–9.8)
eGFR  30–59 70 1 1.4 (0.2–10.4)
eGFR 30 4 0 —
CI  confidence interval; TE  thromboembolism; other abbreviations as in Table 1.verall population. Due to the small number of individualsith CHADS2 score 0, there were no events in the eGFR
30 ml/min/1.73 m2 category, and the rate of IS/TE could
not be calculated for this particular category, and CIs for
event rates in other subgroups of renal function were wide.
Rates of stroke/TE were 3.3% and 7% at 1 year in
individuals with eGFR 60 ml/min/1.73 m2 and with
GFR 30 ml/min/1.73 m2, respectively. The correspond-
ing rates of all-cause mortality at 1 year were 4.2% and
17.6%, respectively (Online Fig. 2).
Online Table 2 displays the rates in patients with a
CHA2DS2-VASc score  0 to 1. Only 91 patients with
renal impairment had a CHA2DS2-VASc score  1 and
nly 2 events occurred in this subgroup. No statistically
ignificant differences in IS/TE rates were observed between
ndividuals when this subpopulation was stratified by renal
unction.
Table 3 shows the results from the Cox regression
nalyses, showing the association of risk factors and risk of
S/TE. As a categoric variable (but not as a continuous
ariable), eGFR was an independent predictor of IS/TE in
F at 1 year follow-up—after adjustment for age, sex, and
HADS2 risk factors—but not for baseline characteristics.
enal impairment did not significantly increase the risk of
S/TE in univariate analyses or after adjustment for
HADS2 risk factors, age, sex, or baseline characteristics at
1 year. When considered as a continuous variable, eGFR
was also not associated with an increased risk of IS/TE at 1
year.
Online Table 3 shows analogous results from Cox regres-
sion analyses after excluding patients on a regimen of
vitamin K antagonists at baseline (n 3,592; 60.8%). Renal
Renal Impairment and Risk of Stroke/TE:su ts From Cox Regre sion AnalysesTable 3 Renal Impairme t a d Risk of Stroke/TE:Results From Cox Regression Analyses
1-Yr Follow-Up
HR (95% CI)
Univariate analysis
Renal impairment 1.05 (0.76–1.46)
eGFR (categoric variable) 1.15 (0.90–1.47)
Adjusted for sex and age
Renal impairment 1.03 (0.73–1.43)
eGFR (categoric variable) 1.07 (0.82–1.40)
Female 1.16 (0.84–1.61)
Age/5-yr increase 1.04 (0.99–1.02)
Adjusted for CHADS2 risk factors
Renal impairment 1.06 (0.75–1.49)
eGFR (categoric variable) 1.09 (0.84–1.41)
Heart failure 0.91 (0.65–1.27)
Hypertension 1.22 (0.88–1.68)
Age  75 yrs 1.25 (0.77–2.02)
Diabetes mellitus 1.22 (0.82–1.80)
Previous stroke/TE 0.88 (0.62–1.26)
Adjusted for baseline characteristics*
Renal impairment 1.09 (0.77–1.55)
eGFR (categoric variable) 1.08 (0.83–1.41)
*Adjusted for Table 1 risk factors that were statistically significant (p 0.05), and including age as
a continuous covariate, the result is only displayed for renal impairment.
HR  hazard ratio; other abbreviations as in Tables 1 and 2.
bC
t
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Renal Impairment and Stroke Risk in AF May 21, 2013:2079–87impairment was not an independent predictor for IS/TE on
univariate analysis (HR: 1.51; 95% CI: 0.93 to 2.44), after
adjusting for age/sex (HR: 1.16; 95% CI: 0.71 to 1.90),
CHADS2 risk factors (HR: 1.20; 95% CI: 0.73 to 1.96), or
baseline characteristics (HR: 0.87; 95% CI: 0.46 to 1.65) at
1 year of follow-up.
The Forest plots in Figure 2 illustrate the results from
Cox regression analyses evaluating differences in IS/TE risk
according to renal function, confirming that renal impair-
ment and eGFR did not significantly increase the risk of
IS/TE after univariate or multivariate models at 1 year.
Table 4 illustrates the impact of adding renal impairment
to the CHADS2 and CHA2DS2-VASc scores, as measured
y NRI, IDI, and c-statistic. Online Table 4 shows the
same analysis confined to only those patients with at least 1
year of follow-up (294 IS/TE events in 2,663 individuals
over the study period).
Figure 2 Risk of Stroke/Thromboembolism
With Renal Impairment
Results from Cox regression analyses. CHADS2  congestive heart failure,
hypertension, age 75 years, diabetes, previous stroke; eGFR  estimated
glomerular filtration rate.
NRI and IDI by Adding Renal Impairment to the CHADS2 and CHA2Table 4 NRI and IDI by Adding Renal Impairment to the CHADS
Patients Reclassified (%)
Patients With Event
(n  434)
Patients Without Event
(n  5,478)
CHADS2 Model 1 31 (7.1) 469 (8.6)
CHADS2 Model 2 54 (12.4) 957 (17.5)
CHADS2 Model 3 31 (7.1) 469 (8.6)
CHADS2 Model 4 5 (1.2) 55 (1.0)
CHA2DS2VASc Model 1 2 (0.5) 127 (2.3)
CHA2DS2VASc Model 2 2 (0.5) 238 (4.3)
CHA2DS2VASc Model 3 2 (0.5) 127 (2.3)
CHA2DS2VASc Model 4 0 (0.0) 5 (0.1)
The net reclassification improvement (NRI) focuses on reclassification tables constructed separat
renal impairment (i.e., increased CHADS2 score for events by adding renal impairment counts pos
he receiver operator characteristic curve (AUC) (c-statistic) by adding the additional risk factor to C
nd focuses on differences between integrated sensitivity and specificity for models with and with
Model 1  1 point for renal impairment; Model 2  1 point for eGFR  30–59, and 2 points for eGFR
Model 4  1 point for eGFR 30; other abbreviations as in Tables 1 and 2.In the overall study population, the c-statistic for the
CHADS2 (HR: 0.64; 95% CI: 0.61 to 0.67) and
CHA2DS2-VASC (HR: 0.64; 95% CI: 0.62 to 0.67) were
similar. There was no statistically significant improvement
in either the CHADS2 or the CHA2DS2-VASc scoring
systems by the addition of renal function, regardless of the
4 models used to add renal function to the risk scores, or
method of estimating reclassification (i.e., NRI or IDI)
(Table 4). This was still evident even when the analysis was
confined to only those patients with at least 1 year of
follow-up (Online Table 4).
Discussion
In this study amongst a large “real-world” cohort of indi-
viduals with nonvalvular AF, we have shown for the first
time that adding renal impairment to existing stroke risk
stratification systems for IS/TE (CHADS2 and CHA2DS2-
VASc) did not independently add to the predictive value of
these scores at 1 year of follow-up, whether it was defined by
serum creatinine level or the eGFR or whether the analysis
was confined to only those patients with at least 1 year of
follow-up. Second, we show that renal impairment by both
creatinine and eGFR definitions was associated with higher
crude rates of stroke/TE at 1 year compared with those with
normal renal function, but renal impairment was not inde-
pendently associated with increased risk of stroke/TE at 1
year.
Although it has been well-recognized that renal impair-
ment is a risk factor for IS/TE in AF patients, renal
impairment has not been included in the CHADS2 or
HA2DS2-VASc scores, due to lack of large prospective
cohort data validating the additive value of renal impairment
to these scores. Trial datasets would not answer this
question, because severe renal impairment was often an
exclusion criteria for clinical trials of IS prevention in AF.
One highly selected cohort of AF patients undergoing
ablation did suggest an additive value of renal dysfunction to
ASc Scoresd CHA2DS2VASc Scores
NRI IDI
RI SE Z
p
Value IDI AUC*
p
Value
015 0.011 0.03 0.49 0.0001 0.004 0.41
051 0.010 0.27 0.61 0.0001 0.001 0.57
016 0.011 0.08 0.47 0.0001 0.007 0.40
002 0.011 0.54 0.71 0.0001 0.0001 0.44
018 0.008 0.90 0.18 0.0001 0.005 0.44
039 0.008 0.80 0.21 0.0002 0.014 0.30
018 0.008 0.90 0.18 0.0001 0.005 0.44
001 0.009 0.05 0.48 0.0000 0.0001 0.25
atients with and without event and quantifies the correct movement in CHADS2 score by adding
and increased CHADS2 score for non-events counts negatively). *Improvement in the area under
and CHA2DS2VASc. The integrated discrimination improvement (IDI) does not require risk groups
al impairment (37).DS2V2 an
N
0.
0.
0.
0.
0.
0.
0.
0.
ely for p
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ci
fi
c
f
s
C
C
C
c
a
a
a
m
c
a
I
T
2085JACC Vol. 61, No. 20, 2013 Banerjee et al.
May 21, 2013:2079–87 Renal Impairment and Stroke Risk in AFthe CHA2DS2-VASc score, but the improvement in the
-statistic was marginal (from 0.84 to 0.88) (30).
In the present larger study, we found no significant
mprovement in c-statistics, and in our analyses of reclassi-
cation, there was reduced specificity despite a slight in-
rease in sensitivity, leading to no additional predictive value
or IS/TE, when renal impairment (both by eGFR and
erum creatinine level) was added to the CHADS2 or
HA2DS2-VASc scores. On the basis of our analyses, renal
impairment should not be added to the CHADS2 or
HA2DS2-VASc scores during routine risk stratification of
AF patients for IS/TE. Indeed, renal impairment is com-
monly associated with the various IS risk factors listed
within the CHADS2 or CHA2DS2-VASc scores; thus, the
lack of an independent additive predictive value might
perhaps be unsurprising.
In the present study, we confirm previous observations
that renal impairment, whether defined by serum creatinine
level or eGFR, was associated with a more severe risk factor
profile in terms of comorbidities and higher risk of IS/TE as
estimated by validated risk stratification scores, compared
with normal renal function (14–16). The Cox regression
analyses suggest that renal impairment is a contributing risk
factor for IS/TE in AF overall, but due to small numbers of
individuals with low or moderate risk (CHADS2 or
HA2DS2-VASc scores of 0 and 1, respectively), the risk of
IS/TE in these subgroups could not be conclusively studied
in the present population. In the recent study by Olesen et
al. (15), adjusted HRs for risk of IS/TE associated with
non–end-stage CKD (HR: 1.49; 95% CI: 1.38 to 1.59) and
end-stage CKD requiring renal replacement therapy (HR:
1.83; 95% CI: 1.57 to 2.14) were comparable to the
observations in our population. Indeed, observed event rates
by renal function in the study by Olesen et al. (15) were also
similar to the present study, consistent with the considerable
risk of IS/TE in AF patients with renal impairment.
Anticoagulation with VKA is associated with a signifi-
cant risk reduction for IS/TE among patients with renal
impairment, but the increased risk of bleeding in the same
patient group and inconclusive data with regard to indica-
tions for oral anticoagulation (OAC) complicate the deci-
sion to start VKA in AF patients with renal impairment
(15,28). As previously noted, the novel oral anticoagulant
agents are predominantly renally excreted, and there are
limited data with regard to their use in (severe) renal
impairment (15,39). Risk stratification schemes such as
CHADS2 or CHA2DS2-VASc scores are well-validated in
the identification of patients at risk of IS/TE to guide the
decision to initiate OAC (39), and our data suggest that
renal impairment need not be added to these scores.
Study limitations. The limitations of this registry include
the inherent limitations of diagnostic coding and case
ascertainment, particularly if an enrolled patient moved
away from the area or had an outcome event in another area.
Most patients with IS/TE, as far as it is identified, are likely
to be seen in 1 department of our institution and not in any Fother institution. It is possible that some patients had AF
before our first recorded episode of AF. The nonrandom-
ized cohort design does not exclude the possibility of
residual confounding factors, despite statistical adjustment
for several risk factors.
Also, there might be clinical differences between inpa-
tients and outpatients, which would affect the generalizabil-
ity of our findings to the outpatient setting or to AF
diagnosed outside the cardiology department. Inpatients
usually have an acute illness or decompensation of a chronic
illness that leads to hospital stay. For example, heart failure,
which impacts IS/TE risk in our study, might be under-
represented in an outpatient or primary care cohort. Patients
with AF seen in the cardiology department were 53% of all
AF patients seen in the institution and 82% of all AF
patients seen in the several medicine departments of our
institution.
The data with regard to VKA use only reflect baseline
therapy and do not reflect any changes in prescribed
therapies or adherence to therapy (which might have had
multiple changes over time in a “real-world” cohort). Also,
data with regard to the “time in therapeutic range” are not
available for our study population. Because only baseline
creatinine measurements and eGFR calculations are avail-
able, we are unable to comment definitively on changes or
progression of renal impairment or the need for renal
replacement therapy. For the latter, 44 (0.7%) patients had
dialysis at baseline, whereas 131 (2.2%) had dialysis either at
baseline or during follow-up, but a sensitivity analysis where
these patients were excluded from the analysis made no
difference to our observations (data not shown). Indeed,
eGFR is probably the most important indicator of renal
function to take into account, because OAC doses are
usually lower in patients with CKD, and dose changes are
more often necessary (40).
In the Cox regression models and in subsequent testing of
the additional value of eGFR to risk prediction of stroke/
TE, the eGFR categories of 60, 30 to 59, and 30
ml/min/1.73 m2 were used to reflect the eGFR ranges most
ommonly used in clinical practice and to enable generaliz-
bility. Moreover, the analyses described were conducted to
ssess whether renal impairment (i.e., eGFR) could be
dded to existing risk prediction tools in a simple, useable
anner. Thus, our analyses of NRI and IDI did not
onsider the effect of continuous increments of eGFR. In
ny case, eGFR was not associated with increased risk of
S/TE at 1 year, when considered as a continuous variable.
he number of individuals with eGFR 30 ml/min/1.73 m2
in the study population was small, and therefore the
statistical power of analysis in this group might be limited.
However, the proportion of individuals with low eGFR (30
ml/min/1.73 m2) in our population (5.8%) is broadly con-
sistent with other studies (e.g., 9.95% with eGFR 45
ml/min/1.73 m2 in the ATRIA [Anticoagulation and Riskactors in Atrial Fibrillation] study (14)), suggesting that
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clinical practice.
Finally, this study had a specific focus, namely the
additive impact of renal impairment on ischemic stroke risk
stratification with the CHADS2 or CHA2DS2-VASc
cores. It is recognized that renal impairment also in-
reases bleeding risk (with implications for the net
linical benefit), which is beyond the focus of our present
tudy objectives (28).
onclusions
enal impairment was not an independent predictor overall
f IS/TE in patients with AF at 1 year. Adding renal
mpairment, whether defined by serum creatinine level or
GFR, to existing risk scoring systems for stroke/TE
CHADS2 and CHA2DS2-VASc) did not independently
add to the predictive value of these scores.
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